Editas Medicine, Inc. EDIT 深 沪
等待开盘 03-26 09:30:00 美东时间
2.32
+0.070
+3.11%
华盛通- 最 高2.375
- 今 开2.29
- 成交量 103.27万股
- 最 低 2.285
- 昨 收 2.25
- 总市值 2.27亿
- 52周最高 4.5372
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.9101
- 委 比 -42.40%
- 总股本 9787.20万
- 历史最高 99.95
- 量 比 0.79
- 振 幅 4.00%
- 历史最低 0.9101
- 每 手 1
- 风险率 0.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Epstein tapped an elite network for stock, startup tips - WSJ
Jeffrey Epstein reportedly tapped his wide network of powerful contacts to gather insights on stocks, startups, and corporate deals as he blurred the line between networking and potentially sensitive ...
03-18 19:57
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
Editas Medicine Q4 Earnings Assessment
Editas Medicine (NASDAQ:EDIT) reported its Q4 earnings results on Monday, March...
03-09 19:20
Editas Medicine Q4 EPS $(0.06) Beats $(0.25) Estimate, Sales $24.741M Beat $5.595M Estimate
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.25) by 76.19 percent. This is a 85 percent increase over losses of $(0.40) per share from the
03-09 19:17
Editas Medicine posts smaller‑than‑expected Q4 net loss on lower R&D spend
Editas Medicine posts smaller‑than‑expected Q4 net loss on lower R&D spend Overview Gene editing firm's Q4 net loss beat analyst estimates Collaboration and R&D revenue decreased due to prior milestone revenue recognition Company maintains strong cash position with runway into Q3 2027 Outlook Editas
03-09 19:15
BRIEF-Editas Medicine Q4 Net Income USD -5.62 Million Vs. IBES Estimate USD -24.3 Million
BRIEF-Editas Medicine Q4 Net Income USD -5.62 Million Vs. IBES Estimate USD -24.3 Million Mar 09 (Reuters) - Editas Medicine Q4 operating expenses USD 32.496 million. Q4 operating income USD -7.755 million Q4 basic EPS USD -0.06 Q4 EPS USD -0.06 Q4 collaboration and other research and development re
03-09 19:00
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
Editas Medicine reported financial results for Q4 and full year 2025, highlighting significant progress in advancing their lead in vivo gene editing candidate, EDIT-401, which achieved >90% LDL-C reduction in preclinical studies. The company expects to submit an IND/CTA for EDIT-401 by mid-2026 and initiate its first-in-human clinical trial later this year. With a cash runway into Q3 2027, Editas is well-positioned to meet upcoming milestones and...
03-09 11:00
Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine announced that its management will participate in two investor conferences in March: the TD Cowen 46th Annual Health Care Conference on March 2 and the Barclays 28th Annual Global Healthcare Conference on March 12. Both events will feature fireside chats. Live webcasts and 30-day replays of the presentations can be accessed via the company’s website.
02-23 14:00
Editas Medicine Q3 EPS $(0.28) Beats $(0.29) Estimate, Sales $7.543M Beat $5.020M Estimate
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.29) by 5.08 percent. This is a 62.67 percent increase over losses of $(0.75) per share from
2025-11-10 20:21
Editas Medicine Q3 net loss narrows, beats expectations
Overview Editas Q3 net loss decreases to $25.1 mln, beating analyst expectations Collaboration revenue rises to $7.5 mln, driven by BMS milestone achievement Company extends cash runway into Q3 2027, ...
2025-11-10 20:08
